Table 3. Device use and change in Fugl-Meyer scores.

		Supervised Phase					Unsupervised phase
Patient	Initial FM	12-week testing (actual week #)	FM change @ 12-week testing	Supervised phase duration (weeks)	FM change during Supervised phase	Unsupervised phase duration (weeks)	FM change post Supervised phase	FM change from initial test
1	24			26.0	+8	10.0	-4	+4
2	24	11.6	+14	35.6	+12	na		+12
3	29	11.0	+16	24.0	+18	na		+18
4	41			62.9	+12	na		+12
5	53	8.0	+3	27.4	+3	24.0	-3	0
6	29	14.0	+1	37.0	+8	21.1	-4	+4
7	42	8.0	+8	19.0	+10	na		+10
8	14	10.4	+7	27.0	+8	na		+8
9	45	11.9	+2	11.9	+2	40.4	-9	-7
Mean (SD)	33.4 (12.5)	10.7 (2.1)	7.3 (5.9)*	30.1 (14.5)	+9.0 (4.8)†	24.0 (12.6)	-5.0 (2.7)	+6.8 (7.4)‡

* t-test p = 0.017

^† t-test p = 0.00053

^‡ t-test p = 0.026

na–not applicable as these patients did not have re-evaluation following an Unsupervised phase